Abstract: The invention provides a clonal cell line derived from a liver cancer cell line, preferably derived from a Huh7 hepatocarcinoma cell line, engineered to produce and secrete viral particles containing pregenomic RNA of the hepatitis B virus (HBV), predominantly over DNA of HBV, to calibrate quantitative HBV RNA assays.

Abstract: The invention features compositions and methods for introducing mutations into the hepatitis B virus (HBV) genome.

Abstract: The present invention relates to a FUBPI inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of FUBPI inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules, such as oligonucleotides including siRNA, shRNA and antisense oligonucleotides, which are complementary to FUBPI and capable of reducing a FUBPI mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection.

Abstract: The netrin-1 protein displays anti-inflammatory activity in the liver and is an unexpected proinflammatory factor in CLD. The present invention provides for blocking or capturing netrin-1 in the liver for treating liver inflammation, and thus methods for treating liver inflammation. To perform this, the invention makes use of a polyclonal or monoclonal antibody specifically binding to netrin-1, including a series of humanized monoclonal antibodies.

Abstract: The present invention relates to a FUBP1 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of FUBP1 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules, such as oligonucleotides including siRNA, shRNA and antisense oligonucleotides, which are complementary to FUBP1 and capable of reducing a FUBP1 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection.

Abstract: An inhibitor for use for preventing and/or treating an infection with hepatitis B virus (HBV) and an in vitro screening method for the identification of a candidate compound suitable for preventing and/or treating an infection with hepatitis B virus is provided.

Abstract: The present invention relates to a FUBP1 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of FUBP1 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules, such as oligonucleotides including siRNA, shRNA and antisense oligonucleotides, which are complementary to FUBP1 and capable of reducing a FUBP1 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection.

Abstract: The present invention concerns an inhibitor for use for preventing and/or treating an infection with hepatitis B virus (HBV) and an in vitro screening method for the identification of a candidate compound suitable for preventing and/or treating an infection with hepatitis B virus. Inventors show that the knock-down of histone chaperone HIRA before HBV inoculation led to a strong decrease in HBV cccDNA (covalently closed circular DNA) accumulation and stable rcDNA (relaxed circular DNA) levels, in HepG2-NTCP cell line, indicating either a possible incomplete or delayed rcDNA to cccDNA transition. This effect was independent from HBx protein expression in Primary human hepatocytes (PHH). HIRA is able to interact with cccDNA and its recruitment is concomitant with deposition of histone variant H3.3 in HepG2-NTCP cell line. HIRA was able to interact with HBc (HBV capsid protein) in infected hepatocytes and in an HepaRG cell line expressing HBc in an inducible manner.

Abstract: The invention relates to the use of an uridine derivative of formula (I); wherein —R1 represents monohalogenated alkynyl or dihalogenated alkenyl; —R2 is chosen from among hydrogen, hydroxyl, O-alkyl, O—CO alkyl and halogen; —R3 is chosen from among hydrogen, hydroxyl, O-alkyl, O—CO alkyl, halogen, SH, S-alkyl and N3; and —R4 is chosen from among hydroxyl, O-alkyl, O—CO alkyl, O-phosphate, O-diphosphate, O-triphosphate and O phosphonate, as well as its possible tautomers, its possible pharmaceutically acceptable addition salts with an acid or a base, and its N-oxide forms, for the preparation of a drug having antiviral activity against a Flaviviridae.

Abstract: A method for measuring the replication capacity of HBV, e.g.

Abstract: The invention provides a method of preparation of HBV genomic amplicons which makes it possible, using the same amplicon obtained from a patient, to evaluate HBV strains resistant to antiviral agents by analysing, their genotype, their phenotype and their replicative capacity. The method of the invention guarantees to obtain the closest in vitro replication capability compared to the in vivo replication and ensures that the influences of all the mutations present on a viral genome are taken into account when evaluating the drug sensitivity and the replicative capacity.